Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Tanner

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Annals of Internal Medicine|November 20, 2018
Risk scores overestimated risk for CVD in newly diagnosed type 2 diabetesMichael Tanner
Annals of Internal Medicine|December 20, 2016
In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosisMichael Tanner
Annals of Internal Medicine|November 16, 2020
In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA<sub>1c</sub> and SBP and may reduce body weightMichael Tanner
Annals of Internal Medicine|May 31, 2021
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAsMichael Tanner
Annals of Internal Medicine|October 3, 2022
USPSTF recommends against beta carotene or vitamin E supplements for preventing CVD or cancer in adultsMichael Tanner
Annals of Internal Medicine|April 5, 2021
In at-risk patients without CVD, polypill plus aspirin reduced a composite of major CV events at 4.6 yMichael Tanner
Annals of Internal Medicine|October 6, 2025
In insulin-naive T2D, fixed-dose weekly efsitora was noninferior to daily glargine for reducing HbA<sub>1c</sub> at 52 wkMichael Tanner,
Annals of Internal Medicine|July 1, 2024
In T1DM without CVD, the LIFE-T1D model predicted lifetime risk for CVD and non-CVD mortalityMichael Tanner
Annals of Internal Medicine|June 1, 2026
Statin therapy increased risk for 4 of 66 adverse outcomes listed in product labels compared with placebo at a median 4.5 yMichael Tanner,
Annals of Internal Medicine|May 31, 2021
USPSTF recommends against screening adults in the general population for asymptomatic carotid artery stenosisMichael Tanner
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Annals of Internal Medicine|November 20, 2018
Risk scores overestimated risk for CVD in newly diagnosed type 2 diabetesMichael Tanner
Annals of Internal Medicine|December 20, 2016
In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosisMichael Tanner
Annals of Internal Medicine|November 16, 2020
In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA<sub>1c</sub> and SBP and may reduce body weightMichael Tanner
Annals of Internal Medicine|May 31, 2021
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAsMichael Tanner
Annals of Internal Medicine|October 3, 2022
USPSTF recommends against beta carotene or vitamin E supplements for preventing CVD or cancer in adultsMichael Tanner
Annals of Internal Medicine|April 5, 2021
In at-risk patients without CVD, polypill plus aspirin reduced a composite of major CV events at 4.6 yMichael Tanner
Annals of Internal Medicine|October 6, 2025
In insulin-naive T2D, fixed-dose weekly efsitora was noninferior to daily glargine for reducing HbA<sub>1c</sub> at 52 wkMichael Tanner,
Annals of Internal Medicine|July 1, 2024
In T1DM without CVD, the LIFE-T1D model predicted lifetime risk for CVD and non-CVD mortalityMichael Tanner
Annals of Internal Medicine|June 1, 2026
Statin therapy increased risk for 4 of 66 adverse outcomes listed in product labels compared with placebo at a median 4.5 yMichael Tanner,
Annals of Internal Medicine|May 31, 2021
USPSTF recommends against screening adults in the general population for asymptomatic carotid artery stenosisMichael Tanner
Pageof 6